EICHORCondition: Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance · Sponsor: AstraZeneca
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Adult patients (≥ 18 years old) * Patients with histologically or cytologically proven NSCLC * Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks. * Informed patients who consent to participate in the study as per local regulations. Exclusion Criteria: * Patients participating in an interventional clinical trial for NSCLC\* \* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment * Patients already enrolled in another module of the cohort in UMBREALUNG * Patients under safeguard of justice, curatorship or guardianship
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Research Site | Aix-en-Provence, France | Recruiting |
| Research Site | Angers, France | Recruiting |
| Research Site | Aurillac, France | Recruiting |
| Research Site | Auxerre, France | Recruiting |
| Research Site | Avignon, France | Recruiting |
| Research Site | Bezannes, France | Not Yet Recruiting |
| Research Site | Béziers, France | Not Yet Recruiting |
| Research Site | Blois, France | Recruiting |
| Research Site | Bordeaux, France | Recruiting |
| Research Site | Bourg-en-Bresse, France | Recruiting |
| Research Site | Caen, France | Not Yet Recruiting |
| Research Site | Carcassonne, France | Recruiting |
+ 40 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726720